Archive for the ‘Bio-Wire’ Category

Questcor Gets a Bid After Q1 2013, Volatility Spikes

05.16.2013 · Posted in Bio-Wire

Questcor Gets a Bid After Q1 2013, Volatility Spikes Volatility has increased significantly for many biotech names, including Questcor Pharmaceuticals (NASDAQ: QCOR) – which has been undergoing a major short squeeze ever since the company reported first quarter results on April 30th 2013. Although the company reported a drop in sales of its flagship product ...

Comments Off Tags:

Amarin Reports Solid Vascepa TRx Growth, Stock Holds Its Ground

05.13.2013 · Posted in Bio-Wire

Amarin Reports Solid Vascepa TRx Growth, Stock Holds Its Ground Last week was quite decent for Amarin Corporation (NASDAQ: AMRN) investors, who saw a 6% rally last Friday in reaction to the company’s Q1 2013 financial results. Of particular interest was the continued growth in Vascepa (icosapent ethyl) capsules, which were approved for hypertriglyceridemia patients ...

Comments Off Tags:

Dendreon Shocks Market With PROVENGE Sales Decline In Q1 2013

05.09.2013 · Posted in Bio-Wire

Today Dendreon (NASDAQ: DNDN) shocked the market after reporting an extremely disappointing $67.6 M in PROVENGE (sipuleucel-T) sales for Q1 2013, representing a 17.56% decline relative to $82 M in revenue reported in Q1 2012. The net loss for the quarter did also decline to $72 million relative to a net loss of $103.9  M ...

Comments Off Tags:

Sarepta Therapeutics: Notes on Q1 2013

05.09.2013 · Posted in Bio-Wire

Sarepta Therapeutics (NASDAQ: SRPT) held a conference call for the Q1 2013 earnings starting at 8:00 AM EDT. The call was focused on eteplirsen – a treatment for Duchenne Muscular Dystrophy that completed and reported Phase IIB results in October 2013. Sarepta is a company that focuses on RNA therapeutics, and is currently focusing on ...

Comments Off Tags:

Bracing for Dendreon Q1 2013 Earnings – All Eyes On PROVENGE

05.08.2013 · Posted in Bio-Wire

  Today, Dendreon (NASDAQ: DNDN) shareholders will brace for the company’s Q1 2013 earnings, which will be discussed in a conference call on Thursday at 9:00 AM EDT. Dendreon, which has been operating at steep losses years after the market launch of its flagship product PROVENGE® (sipuleucel-T), is still attempting to reduce manufacturing costs of ...

Comments Off Tags:

Celgene’s Revlimid Approaches FDA Decision For MCL Indication

05.07.2013 · Posted in Bio-Wire

Celgene Corporation (NASDAQ: CELG) remains just under its 52-week high of $128.52 per share as the market continues to reflect the company’s financial and developmental success halfway throughout the new year. The drug developer has a huge and highly diversified pipeline although the most prominent drug development programs are in the oncology/hematology indications. In their ...

Comments Off Tags:

Huge Potential but Tough Entry for Female Sexual Dysfunction Drugs

05.07.2013 · Posted in Bio-Wire, Featured

Female Sexual Dysfunction (FSD) is often overshadowed by the more prominent erectile dysfunction market. While companies like Pfizer (NYSE: PFE) recruit the likes of Bob Dole and other prominent celebrities to help push Viagra, the attention on FSD has been lacking to say the least. This obscures an analysis of a National Health and Social ...

Comments Off Tags: , ,

Arena & VIVUS Weaken On Poor Obesity Drug Prospects In Europe

05.07.2013 · Posted in Bio-Wire

Arena & VIVUS Weaken On Poor Obesity Drug Prospects In Europe Responding to news that the company would withdraw its MAA (Marketing Authorization Application) for Belviq (lorcaserin) from the EMA (link), shares of Arena Pharmaceuticals (NASDAQ: ARNA) tanked by 9.2% last Friday as investors questioned whether obesity drugs had a future in the EU market. ...

Comments Off Tags: ,

Bio-Wire Weekly: April 29 – May 3rd, 2013

05.06.2013 · Posted in Bio-Wire, Prime Content

Bio-Wire Weekly: April 29 – May 3rd, 2013 To get this email earlier, sign up for our email list The Newsmakers: 1.)    Auxilium Pharmaceuticals (NASDAQ: AUXL) Auxilium Pharma was down about 8% in the last week after the company released Q1 2013 earnings on Monday, April 29th (press release) as well as a corporate update in which ...

Comments Off Tags: , , , , ,

Regeneron Study: EYLEA Growth Potential

05.06.2013 · Posted in Bio-Wire

Regeneron Pharmaceuticals (NASDAQ: REGN) has received an immense amount of attention in the past year, and has doubled the wealth of shareholders primarily due to the shockingly good performance of the VEGF inhibitor EYLEA (Aflibercept) in the wet AMD indication – particular in Q1 2013 (or Q4 2012 fiscally, for the company). The company reported ...

Comments Off Tags: